Eisai and Janssen Pharmaceutica Announce Strategic Alliance For New Proton Pump Inhibitor
NEW BRUNSWICK, N.J., April 15, 1997 - Eisai Co., Ltd. of Tokyo and Janssen Pharmaceutica, N.V., of Belgium, an affiliate of Johnson & Johnson of New Brunswick, NJ, today announced a strategic alliance for rabeprazole (rabeprazole sodium, Eisai code number: E3810), an investigational new drug for duodenal ulcers, gastric ulcers and gastroesophageal reflux disease.
Under this agreement, Eisai and Janssen will copromote rabeprazole in the U.S., U.K., Germany, and France. Janssen will have an exclusive license to market rabeprazole in other territories excluding Japan and other countries in Asia; Italy; Spain; Belgium; Holland. In Italy and Spain, Janssen will have a semiexclusive license. In Spain, Eisai will retain the right to copromote or comarket rabeprazole.
Eisai will receive milestone payments from Janssen according to this agreement.
Rabeprazole is a proton pump inhibitor synthesized by Eisai in Japan. The compound is being developed by Eisai in Japan, the U.S., and Europe. Under the trademark of PARIET, the compound is under review for marketing approval by the Ministry of Health and Welfare in Japan, and by the Medicines Control Agency (MCA) in the U.K. Rabeprazole is in Phase III clinical trials in the U.S.
Johnson & Johnson is the world's largest and most comprehensive manufacturer of health care products serving the consumer, pharmaceutical, diagnostics and professional markets. Johnson & Johnson has more than 170 operating companies in 50 countries around the world, selling products in more than 175 nations.
Eisai Co., Ltd., based in Tokyo (President and CEO: Haruo Naito), is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of $2.6 billion in fiscal year 1995 with approximately 14 percent of sales spent for research and development.
- END -